Therapeutic Implications of Psilocybin in the Wake of Decriminalization
Nikola Lash, George Tadros, Eman Tadros
Integrative and Complementary Therapies June 1, 2024 DOI: 10.1089/ict.2024.27206.nl (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Decriminalization Wake Hallucinogen Criminology Aerospace engineering |
| Citations | 1 |
| Key findings | Psilocybin shows therapeutic potential for mental health disorders and addiction, with cost-effectiveness and low risk of addiction or overdose, but requires ethical prescription and strategic legalization. |
Abstract
Psilocybin fungi, also more informally known as psychedelic mushrooms, have a rich, cultural history and were criminalized in the 1970s. However, recent developments, including Food and Drug Administration breakthrough status and state-level legalization, revive interest in these substances. They may be able to treat many disorders without the addictiveness or risk of overdose of cocaine, heroin, methamphetamine, and other psychoactive chemicals. This article analyzes the therapeutic potential and economic impact of psilocybin amid its nationwide decriminalization. Oregon and Colorado are at the forefront, anticipating changes in legislation, while approximately 25 states are contemplating measures. The cost-effectiveness of psilocybin in the treatment of mental health disorders, addiction, and positive legal indications highlights its appeal. Yet, ethical considerations, careful prescription methods, and strategic legalization are highlighted. This article calls for continuous research, adherence and understanding of ethical standards, and a holistic approach to psilocybin’s accessibility for potential therapeutic advantages.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |
Citations in the library
Cites 24
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Long-term follow-up of psilocybin-facilitated smoking cessation The American Journal of Drug and Alcohol Abuse July 21, 2016
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
and 19 more in the library